ReviewNephron2025
Bench to Bedside: Translating Discoveries to Clinical Care in Kidney Disease.
Review in Nephron, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAcute kidney injury (AKI) pathophysiology and repair are heterogenous processes, and clinical outcomes are difficult to predict. As a result, promising treatments in preclinical models have failed to translate to human subjects, and treatment options for AKI are primarily supportive. SUMMARY: To address this, one of the AKI and CRRT 2025 preconference symposium plenary sessions showcased cutting-edge translational work to guide the scientific community of AKI investigators. Topics included those focused on stratifying risk for AKI reflected in the concept of kidney fitness, characterizing the molecular phenotypes of AKI, improving diagnostics, and identifying novel therapeutic targets. KEY MESSAGES: This article provides a review of these topics and a summary of how they address challenges to translating new therapies in AKI from bench to bedside.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.